1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsTreating Hereditary Rare Diseases with In Vivo Precision Genetic Medicines (THRIVE) program is sponsored by Advanced Research Projects Agency for Health (ARPA-H), HHS. This opportunity supports mission-aligned projects and measurable outcomes.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
#### Looking for contract opportunity help?
* **Contract Opportunity Type:** Solicitation (Updated) * **Updated Published Date:** Dec 15, 2025 04:57 pm EST * **Original Published Date:**Sep 25, 2025 09:15 am EDT * **Updated Date Offers Due:** Dec 22, 2025 03:00 pm EST * **Original Date Offers Due:**Dec 19, 2025 11:59 pm EST * **Inactive Policy:**15 days after date offers due * **Updated Inactive Date:** Jan 06, 2026 * **Original Inactive Date:**Jan 03, 2026 * **Original Set Aside:**No Set aside used * **Product Service Code:** AN13 - HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT * 541714 - Research and Development in Biotechnology (except Nanobiotechnology) * **Place of Performance:**Washington Amendment 6: Revised PowerPoint presentation template and Cost Proposal Spreadsheet Template The purpose of this amendment is to provide a revised version of the PowerPoint template for the presentation.
Changes are indicated in red (see Slide Nos. 7, 8, and 10). Proposers are instructed to use this version of the template when creating a PowerPoint for the presentation.
In addition, the amendment includes the cost proposal spreadsheet template for the proposal submission. As a reminder, cost proposal spreadsheets are not due until full proposals are due (February 5, 2026 by 03:00PM ET). Amendment 5: PowerPoint presentation template The purpose of this amendment is to provide the template for the PowerPoint presentation.
Please see the Attachments section for the template. Amendment 4: PowerPoint presentation The purpose of this amendment is to add a virtual PowerPoint presentation to the evaluation process. This additional step requires submission of PowerPoint presentation slides, a Gantt chart, and an optional appendix in PDF format.
For full details, please see the revised ISO, with changes identified in red font, attached to this amendment. Please note, the deadline for the PowerPoint presentation submission is **December 22, 2025 at 3:00PM E. T.
**The virtual PowerPoint presentations are expected to be held from **January 5th to January 16th, 2026.
** Amendment 3: Team Organization and Capabilities Section The purpose of this amendment is to clarify that the following information, requested in the Teaming Organization and Capabilities section of the Solution Summary, may be included in the Table for Key Personnel: _Provide the name, position, and institution of each key team member and describe in 1-2 sentences the skills and experience they bring to the team.
_ If included in the Table for Key Personnel, this information will not count towards the (3) page Solution Summary page limit, however, the Table for Key Personnel must still not exceed (1) page in length. In addition, the Q&A deadline is extended to October 30, 2025 at 11:59PM ET. Amendment 2: Changes to the ISO The purpose of this amendment is to amend the THRIVE ISO.
An updated version of the ISO and an updated version of the ISO with tracked changes are included as attachments. Changes to the ISO include: 1. Cost share is now strongly encouraged instead of mandatory.
2. Multi-party teaming arrangements are no longer required. 3.
ARPA-H's involvement with regulatory facilitation has been clarified. Please review the amended ISO for all changes. Amendment 1: Added the Frequently Asked Questions (FAQ) to the list of attachments.
The Advanced Research Projects Agency for Health (ARPA-H)T reating H ereditary R are diseases with I n V ivo precision genetic m E dicines (THRIVE) program envisions a future where patients can opt for one-time therapeutic interventions designed to slow, reverse, or cure disease, harnessing revolutionary technologies and a rapidly evolving understanding of the genetic underpinnings of the biological processes that lead to disease.
Interested parties are invited to review the attached THRIVE Innovative Solutions Opening (ISO) ARPA-H -SOL-25-122. For detailed information regarding Proposers' Day review Special Notice (SN) ARPA-H-SN-25-131. Solution summaries are due**October 31, 2025, 11:59 PM ET**.
For more information about THRIVE, please visit:https://arpa-h.
gov/explore-funding/programs/thrive * 1301 K Street NW Suite 1200 West * **Feb 20, 2026 11:55 pm EST**Solicitation (Updated) * **Jan 09, 2026 04:56 pm EST**Solicitation (Updated) * **Jan 07, 2026 12:00 am EST**Solicitation (Updated) * **Dec 02, 2025 06:04 pm EST**Solicitation (Updated) * **Nov 14, 2025 09:50 pm EST**Solicitation (Updated) * **Oct 27, 2025 05:47 pm EDT**Solicitation (Updated) * **Oct 17, 2025 03:49 pm EDT**Solicitation (Updated) * **Oct 09, 2025 11:25 am EDT**Solicitation (Updated) * **Sep 25, 2025 11:02 am EDT**Solicitation (Updated) * **Sep 25, 2025 09:15 am EDT**Solicitation (Original) * **Sep 25, 2025 09:02 am EDT**Special Notice (Original)
According to the current listing, eligibility includes: Researchers and developers focused on precision genetic medicines and integrated platform technologies to treat hereditary rare diseases. Confirm the full requirements in the official notice before applying.
Treating Hereditary Rare Diseases with In Vivo Precision Genetic Medicines (THRIVE) program is funded by Advanced Research Projects Agency for Health (ARPA-H), HHS. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
ARPA-H's 2026 SBIR/STTR BAA opens seven transformative health topics with $600K Phase I and $3.5M Phase II contracts — non-dilutive, milestone-driven money. The July 10 Solution Summary gate decides who ever gets to pitch. Here's how the ARPA-H model differs from NIH and how small health-tech firms actually get through the funnel.
Read articleHHS launched STREAM on August 17 through ARPA-H — four technical areas spanning AI-designed herbicides, laser weeders, low-cost chemical sensing, and soil remediation. It runs inside an existing Mission Office ISO, which changes who can apply and how fast the clock moves after you submit.
Read articleThe Emerging Health Innovators solicitation drops on SAM.gov by the end of September 2026 with 16 named topic areas, an eight-year terminal-degree ceiling, and an eligibility screen that bars national labs, FFRDCs, UARCs, and anyone who has ever led an ARPA prime award. Proposers' Day is October 13. Here is how to read the design.
Read article